Glaukos Corporation, Allergan, Ivantis, Inc. are Dominating the Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market in 2019

Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market is expected to grow with the CAGR of 31.7% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-micro-invasive-glaucoma-surgery-migs-devices-market

Global micro invasive glaucoma surgery (MIGS) devices market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global micro invasive glaucoma surgery (MIGS) devices market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance In July, 2019 MicroSurgical Technology (MST), along with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. This is helpful in trimming stent protrusions by minimal invasion. As it is a novel product it will widen the product portfolio and also lead to a rise in the revenue generation.

Glaukos Corporation is the dominating player in global micro invasive glaucoma surgery (MIGS) devices market. The other key players existing in the market includes Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Surgical Vision Inc. and Johnson and Johnson Vision Care Inc.(A subsidiary of Johnson and Johnson Inc.), Microsurgical technology, Molteno Ophthalmic Ltd. ,New world Medical ,Santen Pharmaceutical and Sight Scientific among others.

Micro Invasive Glaucoma Surgery (MIGS) Devices MarketGlaukos Corporation:

Glaukos Corporation was incorporated in 1998.  The company is headquartered in California, U.S.  The company is engaged in building a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.  The company is providing products under glaucoma, corneal health, and retinal disease. The market focus products lie under glaucoma product category. The company is engaged in continuous development of micro invasive glaucoma surgery (MIGS) devices.   

  • In November 2019, Glaukos Corporation stated that it has acquired   Avedro, Inc., which also works in the development of products for corneal health. This acquisition has led to widening of product portfolio. Also, the revenue generation is more.

The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, North America and South America. The company has various subsidiaries like Avedro, Inc. (U.S.), Glaukos Europe GmbH (Europe), Glaukos Canada Inc. (Canada) among others.  

Allergan

Allergan, headquartered in Dublin, Ireland   was founded in 2013. The company is focused on developing, manufacturing, commercializing the branded pharmaceutical device, biologic, surgical and regenerative medicine products for patients around the world. The company has multiple business segments such as   US specialized therapeutics, US general medicine, International and others, in which US specialized therapeutics is the market focused segment. The company is providing products under central nervous system, eye care, gastroenterology, and medical aesthetics. The market focus products lie under eye care product category. The company is engaged in continuous development of micro invasive glaucoma surgery (MIGS) devices market.   

  • In April 2020, Allergan plc declared that China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN Gel Stent for the patients suffering from refractory glaucoma.

The company has wide presence across Europe, North America, South America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as ZELTIQ Aesthetics (U.S.), ALLERGAN LIMITED (U.K), Envy Medical, Inc. (U.S.), Kythera Biopharmaceuticals, Inc. (U.S.), Actavis Group ehf. (Iceland) among others.

Ivantis, Inc.:

Ivantis, Inc. is headquartered in California, U.S. The company is focused on expanding patient treatment and improving outcomes through innovative minimally invasive glaucoma surgical (MIGS) solutions. The company is engaged in providing a product which is also the market focus that is Hydrus Microstent.

  • In August, Ivantis, Inc. announced the FDA approval of its hydrus microstent for minimally invasive glaucoma surgery. This was an excellent innovation for this company and led to the revenue generation.

The company has wide presence across North America, Europe and Asia-pacific.